Literature DB >> 15972516

Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3.

Alison R Kerr1, Gavin K Paterson, Alan Riboldi-Tunnicliffe, Tim J Mitchell.   

Abstract

Complement is known to be involved in protection against systemic infection with Streptococcus pneumoniae. However, less is known about effects of complement within the lungs during pneumococcal pneumonia. By intranasally infecting transgenic mice unable to express complement C3, we investigated the role of complement in pulmonary defenses against S. pneumoniae. It was demonstrated that within the lungs, there is a requirement for C3 during the initial hours of infection. It was found that within 1 h of infection, bacterial loads decreased within lung airways of control mice as C3 protein increased. The lack of C3 resulted in the inability to control growth of wild-type or attenuated pneumococci within the lungs and bloodstream, resulting in an overwhelming inflammatory response and shorter survival times. Our results show that during the initial hours of infection with S. pneumoniae, C3 is protective within the lungs and subsequently plays an important role systemically.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972516      PMCID: PMC1168602          DOI: 10.1128/IAI.73.7.4245-4252.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia.

Authors:  R B Alcantara; L C Preheim; M J Gentry-Nielsen
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Role of HtrA in the virulence and competence of Streptococcus pneumoniae.

Authors:  Yasser Musa Ibrahim; Alison R Kerr; Jackie McCluskey; Tim J Mitchell
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

3.  The moribund state as an experimental endpoint.

Authors:  L A Toth
Journal:  Contemp Top Lab Anim Sci       Date:  1997-05

4.  The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.

Authors:  Jeremy S Brown; Tracy Hussell; Sarah M Gilliland; David W Holden; James C Paton; Michael R Ehrenstein; Mark J Walport; Marina Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

5.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

6.  Degradation of C3 by Streptococcus pneumoniae.

Authors:  C S Angel; M Ruzek; M K Hostetter
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

7.  Activation of human complement by the pneumococcal toxin pneumolysin.

Authors:  J C Paton; B Rowan-Kelly; A Ferrante
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

8.  PspC, a pneumococcal surface protein, binds human factor H.

Authors:  S Dave; A Brooks-Walter; M K Pangburn; L S McDaniel
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Role of Pneumolysin's complement-activating activity during pneumococcal bacteremia in cirrhotic rats.

Authors:  R B Alcantara; L C Preheim; M J Gentry
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

10.  Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection.

Authors:  Alison R Kerr; June J Irvine; Jennifer J Search; Neill A Gingles; Aras Kadioglu; Peter W Andrew; William L McPheat; Charles G Booth; Tim J Mitchell
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more
  27 in total

Review 1.  Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

Authors:  Justin L Wong; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-03-01       Impact factor: 2.878

2.  The effects of PspC on complement-mediated immunity to Streptococcus pneumoniae vary with strain background and capsular serotype.

Authors:  Jose Yuste; Suneeta Khandavilli; Naadir Ansari; Kairya Muttardi; Laura Ismail; C Hyams; Jeffrey Weiser; Timothy Mitchell; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

3.  Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.

Authors:  Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 4.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

5.  Structural determinants of host specificity of complement Factor H recruitment by Streptococcus pneumoniae.

Authors:  David Achila; Aizhuo Liu; Rahul Banerjee; Yue Li; Erik Martinez-Hackert; Jing-Ren Zhang; Honggao Yan
Journal:  Biochem J       Date:  2015-01-15       Impact factor: 3.857

Review 6.  Complement system in lung disease.

Authors:  Pankita H Pandya; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

Review 7.  The protective function of human C-reactive protein in mouse models of Streptococcus pneumoniae infection.

Authors:  Alok Agrawal; Madathilparambil V Suresh; Sanjay K Singh; Donald A Ferguson
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-12       Impact factor: 2.895

8.  Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae.

Authors:  John C Phipps; David M Aronoff; Jeffrey L Curtis; Deepti Goel; Edmund O'Brien; Peter Mancuso
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

9.  The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model.

Authors:  D Bogaert; C M Thompson; K Trzcinski; R Malley; M Lipsitch
Journal:  Vaccine       Date:  2009-11-03       Impact factor: 3.641

Review 10.  Potential role for mucosally active vaccines against pneumococcal pneumonia.

Authors:  Kondwani C Jambo; Enoch Sepako; Robert S Heyderman; Stephen B Gordon
Journal:  Trends Microbiol       Date:  2009-12-22       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.